BrainCool AB (publ) has established direct sales operations in USA
BrainCool Inc is led by VP Bryan Nicholson with the objective to launch BrainCool’s first product on the US market - the IQool™ System.
The temperature management market in the US is dominated by surface cooling products, where Arctic Sun from Becton Dickinson has been the market leader for a longer period. The market was estimated to be worth around MUSD 180 in 2018 and a substantial part of that value consisted of consumables for one-time use.
BrainCool is currently conducting two additional FDA-approval efforts. These pertain to the medical devices RhinoChill™ and Cooral® System, which upon market registration will be part of BrainCool’s product portfolio available for the US direct sales force.
The IQool™ System is currently evaluated in several locations in the US. BrainCool Inc has built a strong infrastructure under Bryan Nicholson’s leadership, supported by an experienced team comprised of Sales and Clinical Support.
Bryan Nicholson, Vice President Sales & Marketing, comments;
- The reason I joined BrainCool was the breadth of innovative products. Single product companies are not built to last and we expect to launch several products in the coming years. Aiming for a solid installed base of the IQool™ System will create a sustainable business in cash flow products. BrainCool is in it for the long run.
BrainCool can adapt to the market demands more rapidly than the existing Target Temperature Management (TTM) companies.
- Our team has listened to the leading clinicians in TTM and introduced a number of usability improvements, as well as training and support plans for the IQool™ System. The market leading product, Arctic Sun, was designed over a decade ago, Bryan adds.
BrainCool is setting the standard for innovation within Advanced TTM devices. The US TTM market is divided into two patient types for Cardiac Care and Neurocritical Care. We have set evaluations for both patient types with the IQool™ System. Our focus is on patient care in large health system to build the need for multiple IQool™ System sales. Clinicians want the IQool™ System due to our durable pads and precise temperature control. Our soft silicone pads can be applied and removed easily to adapt to patient flow in a hospital. Older generation devices have limitations to duration of use.
BrainCool’s CEO, Martin Waleij, comments;
- During the past year, BrainCool has in close collaboration with end-users made further improvements to the software and algorithm in the product and we now have 20 systems in use in various evaluations. The objective is to evolve these into sales and continue to build a considerable base of installed IQool™ Systems this year.
The IQool™ System is an improvement to the existing surface cooling technologies, which have several technical flaws, such as overshooting, inefficient target temperature control, and
temperature fluctuations. The IQool™ System eliminates all these shortcomings by delivering rapid, selective, precise, and controlled cooling.
Follow the progress of BrainCool Inc through the new US website www.braincoolinc.com for all our upcoming events. Last week our team was in Orlando, Florida, for NTI Conference with over 12,000 nurses in attendance (www.aacn.org). The IQool™ System is a next-generation precision surface cooling system intended for temperature management with a focus on three independent anatomical zones: head/ neck, thigh and torso. The IQool™ System quickly and effectively cools adult patients when clinically indicated using easy-to-apply non-stick adhesive pads prefilled with BCCOOL (a non-toxic and bacteria-static cooling agent) that are attached to an automated chiller. The IQool™ engages within seconds, allowing clinicians in a variety of settings to manage patient temperature quickly and effectively.
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
About BrainCool AB (publ)
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.